Literature DB >> 3160882

Effect of parathyroid hormone on myocardial energy metabolism in the rat.

R Baczynski, S G Massry, R Kohan, M Magott, Y Saglikes, N Brautbar.   

Abstract

This study examined the effect of parathyroid hormone (PTH) on myocardial energy production, transfer, and utilization. Rats (150 to 200 g) were injected with 1-84 PTH, 200 U/day i.p., or 1-34 PTH, 200 or 300 U/day i.p., for 4 days. Control animals received the vehicle only. The effect of the simultaneous administration of calcium channel blocker, verapamil, was also examined. Myocardial contents of Pi, ATP, and CP were significantly (P less than 0.01) lower in the 1-84 PTH-treated rats than in control animals. Both 1-84 PTH and 1-34 significantly (P less than 0.01) reduced mitochondrial oxygen consumption without altering ADP:O ratio indicating reduced phosphorylation. 1-84 and 1-34 PTH significantly (P less than 0.01) reduced the activities of mitochondrial and myofibrillar creatine phosphokinase and 1-84 PTH inhibited (P less than 0.01) the activities of mitochondrial Mg ATPase and those of myofibrillar Ca ATPase. There were significant (P less than 0.01) increments in myocardial 45Ca and in total calcium content in 1-84 PTH-treated rats. Verapamil abolished all the effects of 1-84 PTH. Similarly, inactivation of 1-84 PTH abolished its effects. Treatment with 1-84 PTH for 10 days was associated with a significant decrease in cardiac index and mean arterial pressure. Our data demonstrate that both 1-84 and 1-34 PTH impair energy production, transfer, and utilization. These biochemical derangements, if maintained, produce a decrease in cardiac index. It appears that the enhanced entry and the accumulation of calcium in the myocardium, either directly and/or indirectly, are responsible for the action of PTH on energy metabolism of the heart.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3160882     DOI: 10.1038/ki.1985.71

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Evaluation of left ventricular functions in patients with primary hyperparathyroidism: is there any effect of parathyroidectomy?

Authors:  Alper Kepez; Mehmet Yasar; Murat Sunbul; Cigdem Ileri; Oguzhan Deyneli; Bulent Mutlu; Osman Yesildag; Yelda Basaran
Journal:  Wien Klin Wochenschr       Date:  2017-03-17       Impact factor: 1.704

2.  Impact of age on survival predictability of bone turnover markers in hemodialysis patients.

Authors:  Paungpaga Lertdumrongluk; Wei Ling Lau; Jongha Park; Connie M Rhee; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2013-07-30       Impact factor: 5.992

3.  Cardiovascular complications caused by advanced secondary hyperparathyroidism in chronic dialysis patients; special focus on dilated cardiomyopathy.

Authors:  Norihiko Goto; Yoshihiro Tominaga; Susumu Matsuoka; Tetsuhiko Sato; Akio Katayama; Toshihito Haba; Kazuharu Uchida
Journal:  Clin Exp Nephrol       Date:  2005-06       Impact factor: 2.801

Review 4.  Bone and mineral disorders in pre-dialysis CKD.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

5.  On the mechanism of impaired insulin secretion in chronic renal failure.

Authors:  G Z Fadda; S M Hajjar; A F Perna; X J Zhou; L G Lipson; S G Massry
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

6.  The association between parathyroid hormone and mortality in dialysis patients is modified by wasting.

Authors:  Christiane Drechsler; Vera Krane; Diana C Grootendorst; Eberhard Ritz; Karl Winkler; Winfried März; Friedo Dekker; Christoph Wanner
Journal:  Nephrol Dial Transplant       Date:  2009-05-27       Impact factor: 5.992

7.  The evaluation of intracellular energy metabolism in prediabetic patients and patients newly diagnosed with type 2 diabetes mellitus

Authors:  Erkan Dulkadiroğlu; Hüseyin Özden; HÜseyİn Demİrcİ
Journal:  Turk J Med Sci       Date:  2021-02-26       Impact factor: 0.973

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.